brentuximab vedotin
Ligand Summary
a CD30-directed antibody-drug conjugate consisting of three components: the chimeric IgG1 antibody cAC10, specific for human CD30, the microtubule disrupting agent MMAE, and a protease-cleavable linker that covalently attaches MMAE to cAC10
ChEMBL: CHEMBL1742994
DrugCentral: 4964
LyCHI: brentuximab vedotin
Target Activities
10 Activities
Items per page:
10
1 – 10 of 10
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
BINDING AGENT | ||||||
INHIBITOR | ||||||
INHIBITOR | ||||||
INHIBITOR | ||||||
INHIBITOR | ||||||
INHIBITOR | ||||||
INHIBITOR | ||||||
INHIBITOR | ||||||
INHIBITOR | ||||||
INHIBITOR | ||||||